ICER sets out potential review plans for 2020

10 July 2019

The US medicines cost-effectiveness watchdog Institute for Clinical and Economic Review (ICER) has released its preliminary list of potential assessment topics for 2020.

The list is drawn from ICER horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted by the public. The ICER’s topic selection criteria - including the projected timing and likelihood of US Food and Drug Administration approval, and whether a review of the evidence would suggest specific actions for payers, physicians, patients, and policymakers to improve clinical practice – are applied to produce this preliminary list of potential topics.

ICER has already announced that its January 2020 public meeting will review rimegepant (Biohaven), ubrogepant, from Allergan (NYSE: AGN)), and lasmiditan, from Eli Lilly (NYSE: LLY) for the treatment of acute migraine. The list below presents drugs and other health care interventions that are currently identified as potential additional topics for ICER reviews that will conclude after January 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK